Syndax Pharmaceuticals, Inc.
SNDX
$19.50
$0.422.18%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 72.79M | 64.86M | 68.73M | 45.87M | 37.96M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 72.79M | 64.86M | 68.73M | 45.87M | 37.96M |
| Cost of Revenue | 71.24M | 61.48M | 81.35M | 58.38M | 63.51M |
| Gross Profit | 1.54M | 3.39M | -12.62M | -12.51M | -25.55M |
| SG&A Expenses | 41.54M | 37.59M | 49.93M | 44.92M | 43.81M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 112.78M | 99.07M | 131.28M | 103.30M | 107.31M |
| Operating Income | -40.00M | -34.20M | -62.55M | -57.43M | -69.35M |
| Income Before Tax | -49.36M | -42.67M | -68.01M | -60.72M | -71.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.36M | -42.67M | -68.01M | -60.72M | -71.85M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.36M | -42.67M | -68.01M | -60.72M | -71.85M |
| EBIT | -40.00M | -34.20M | -62.55M | -57.43M | -69.35M |
| EBITDA | -39.99M | -34.20M | -62.55M | -57.43M | -69.35M |
| EPS Basic | -0.55 | -0.48 | -0.78 | -0.70 | -0.83 |
| Normalized Basic EPS | -0.35 | -0.30 | -0.49 | -0.44 | -0.52 |
| EPS Diluted | -0.55 | -0.48 | -0.78 | -0.70 | -0.83 |
| Normalized Diluted EPS | -0.35 | -0.30 | -0.49 | -0.44 | -0.52 |
| Average Basic Shares Outstanding | 88.99M | 88.26M | 87.36M | 86.62M | 86.34M |
| Average Diluted Shares Outstanding | 88.99M | 88.26M | 87.36M | 86.62M | 86.34M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |